Patients prioritize reducing recurrence risk yet lack sufficient information about it.
In oncology offices across the United States, a quiet crisis unfolds each time a patient leaves with a treatment plan but without the knowledge or emotional scaffolding to carry the weight of what comes next. A survey of 220 breast cancer patients, presented at the 2025 San Antonio Breast Cancer Symposium, documents what many have long suspected: that the most common form of breast cancer—hormone receptor-positive, HER2-negative—leaves patients underserved by both information and compassion at the very moment they need both most. Nearly a third of early-stage patients in this group went on to experience metastatic recurrence, yet the majority had never been adequately prepared for that possibility. The findings ask a question medicine must answer: what does it mean to treat a disease while leaving the person who carries it largely alone with their fear?
- Among early-stage HR+/HER2− breast cancer patients, 67% wished they had received more survival information at diagnosis—and 22% received none at all.
- Nearly three in ten patients initially diagnosed at early stages went on to experience metastatic recurrence, often without having been warned that this was a meaningful possibility.
- Analysis of over 3,400 social media posts revealed patients living in prolonged fear of late recurrences, frustrated by limited monitoring and blindsided when cancer returned despite treatment compliance.
- Patients with the most common breast cancer subtype reported less access to support services than those with rarer, higher-profile subtypes—compounding an already significant information deficit.
- Researchers are calling for recurrence risk education to be embedded in standard care at diagnosis, alongside emotional support services that currently reach far too few patients.
A woman leaves her oncologist's office with a treatment plan and a fear she cannot name—because no one has given her the language or the resources to face what recurrence might mean. This experience, repeated across the country, has now been formally documented.
Researchers surveyed 220 breast cancer patients in the United States, focusing on those with hormone receptor-positive, HER2-negative disease—the most common early-stage subtype. Of the 57 patients with this diagnosis, two-thirds had been initially diagnosed at early stages, yet nearly three in ten would later experience metastatic recurrence. Despite this risk, most were never adequately informed: 22 percent received no survival information at diagnosis, and 67 percent were offered no emotional support services. Among those who later experienced metastatic recurrence, the gaps were even starker—three-quarters had wanted but never received survival information, and 40 percent had sought emotional support that was never provided.
To capture what surveys alone could not, researchers also examined 3,440 social media posts from patients and caregivers. The posts told a consistent story: people living with persistent fear of late recurrence, frustrated by the absence of long-term monitoring, and shocked when cancer returned despite doing everything right. The psychological weight of uncertainty—and the isolation of carrying it without adequate support—emerged as a defining feature of the patient experience.
Patients themselves were clear about their priorities: limiting the spread of cancer and living as long as possible ranked highest. Yet most lacked sufficient knowledge about their actual recurrence risk or how to influence it. Compounding the problem, HR+/HER2− patients reported less access to support programs than those with rarer, more visible subtypes—leaving those with the most common diagnosis feeling overlooked by the very infrastructure meant to help them.
The findings, presented at the 2025 San Antonio Breast Cancer Symposium, point toward a systemic failure rather than an isolated oversight. Patients need recurrence risk education delivered at diagnosis, emotional support as a standard of care, and the reassurance that their fears are not excessive—but legitimate responses to a disease that demands ongoing vigilance.
A woman sits in an oncologist's office after hearing the words she feared most: breast cancer. The conversation moves quickly through treatment options, survival statistics, next steps. She leaves with a plan but not with what she needed most—a clear picture of what recurrence might look like, or where to find help if fear takes over at three in the morning.
This gap between what patients receive and what they need has now been documented in a survey that captures the lived experience of breast cancer patients in the United States. Researchers analyzed responses from 220 women who participated in an online survey, focusing specifically on those diagnosed with hormone receptor-positive, HER2-negative breast cancer—a common subtype that accounts for the majority of early-stage diagnoses. Of these 220 respondents, 57 had this specific diagnosis. Among those 57, two-thirds were initially diagnosed with early-stage disease, stages I through III. Yet within that group, nearly three in ten would go on to experience metastatic recurrence—the cancer returning in a more advanced form.
The findings reveal a troubling pattern. Among patients initially diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer, roughly one-third wished they had received more information about survival chances and duration at the time of diagnosis. Another quarter wanted emotional support resources they never received. Some patients got nothing at all: 22 percent received no information about survival odds, and 67 percent were offered no emotional support services. The picture becomes sharper when looking at those who later experienced metastatic recurrence. Three-quarters of them had wanted but never received information about survival; 40 percent had sought emotional support that was never offered.
To understand the broader landscape of patient experience, researchers also analyzed 3,440 posts from social media, forums, and blogs written by American patients and caregivers. More than four-fifths came from patients themselves. These posts painted a consistent picture: people worried about late recurrences appearing years after treatment ended, frustrated by the lack of long-term monitoring, shocked when cancer returned despite following their treatment plan, and living with persistent fear of what might come next. The posts revealed something the survey numbers alone could not capture—the psychological weight of uncertainty, the isolation of facing these concerns without adequate information or community support.
When asked what mattered most in their treatment, patients ranked two things at the top: limiting the risk that cancer would spread to other parts of the body, and living as long as possible. Reducing recurrence risk emerged as one of the most important factors shaping how patients felt about their treatment options. Yet despite this clear priority, most patients lacked sufficient knowledge about their actual recurrence risk or what they could do to influence it.
Another disparity emerged in the data. Patients with hormone receptor-positive, HER2-negative breast cancer reported having less access to services and support programs compared to patients with other breast cancer subtypes, such as HER2-positive or triple-negative disease. This matters because those other subtypes have received more research attention and media visibility, leaving patients with the most common form of breast cancer feeling somewhat abandoned by the support infrastructure.
The research, presented at the 2025 San Antonio Breast Cancer Symposium, points to a clear need: patients need better education about their individual recurrence risk, delivered at diagnosis when they are most receptive. They need access to emotional support services as part of standard care. And they need to know that their concerns about late recurrence, about gaps in monitoring, about the fear that never quite goes away—these are not signs of weakness or excessive worry, but legitimate responses to a disease that demands ongoing vigilance. The gap between what patients prioritize and what they receive is not a small oversight. It is a systemic failure that leaves people facing one of life's most serious diagnoses without the information and support they need to move forward.
Notable Quotes
Patients prioritize reducing recurrence risk when ranking treatment options yet lack sufficient information and understanding about it.— Study conclusions presented at 2025 San Antonio Breast Cancer Symposium
The Hearth Conversation Another angle on the story
Why does it matter that two-thirds of these patients wanted information they didn't get?
Because when you're told you have cancer, you're making decisions about your body and your future in a state of shock. If you don't understand your actual risk of recurrence, you can't make informed choices about treatment intensity, follow-up care, or how to structure your life. You're flying blind.
And the emotional support piece—is that just about feeling better, or does it affect outcomes?
It's both. People who feel isolated and afraid make different decisions. They skip appointments, they catastrophize every symptom, they don't advocate for themselves. Support isn't a luxury; it's part of the medical picture.
The survey found that 29% of early-stage patients later experienced metastatic recurrence. That's a significant number. Were those the same people who lacked information?
There's a strong correlation. Three-quarters of the people who recurred had wanted survival information they never got. You can't say information alone prevents recurrence—the biology is what it is—but the lack of information meant they were unprepared, unsupported, and often shocked when it happened.
Why do you think hormone receptor-positive patients have less access to support than other types?
It's a visibility problem. HER2-positive and triple-negative cancers are rarer, so they've gotten more research funding and media attention. HR-positive is the most common type, so it's almost invisible. Paradoxically, the largest group of patients gets the least support infrastructure.
What would change if doctors gave this information at diagnosis?
Everything. Patients could ask better questions. They could find communities of people with their specific diagnosis. They could plan for long-term monitoring instead of being shocked by late recurrence. And they wouldn't feel so alone.